New hope for myeloma patients: iberdomide trial targets suboptimal transplant responses
NCT ID NCT05354557
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug iberdomide can safely improve outcomes for people with multiple myeloma who had a less-than-ideal response after a stem cell transplant and previous maintenance therapy. Sixteen participants will take iberdomide and be monitored for disease progression and side effects. The goal is to see if more patients achieve a complete response within six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (Consent and Followup)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Consent and Follow up)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Consent and Follow-Up only)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Consent and Followup)
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Consent and Follow up)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Consent and Follow Up)
Harrison, New York, 10604, United States
-
Weill Cornell Medical College (Data Collection Only)
New York, New York, 10021, United States